October 21-24, 2022
Sheraton Boston Hotel
Boston, Massachusetts

Conference Cochairs

Thomas F. Gajewski, University of Chicago, Chicago, Illinois
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas
Jedd D. Wolchok, Weill Cornell Medicine, New York, New York

The AACR Special Conference on Tumor Immunology and Immunotherapy is designed to integrate multi-disciplinary facets of basic cancer immunology and immunotherapy to broaden our understanding of ways to harness the immune system to treat cancer. The hallmark of this series is also to encourage the effective exchange of ideas between basic cancer immunologists, non-immunologists, and clinical oncologists in order to develop approaches that translate to outcomes. This year’s program will feature international leaders in the field, who will expand our knowledge of the microbiome, alternative checkpoints beyond PD-1 and CTLA-4, imaging and other new technologies, adoptive T cell therapy with a focus on challenges in solid tumors, and myeloid cells in the tumor microenvironment. These world-renowned oncologists and researchers will offer their insights on mechanisms of immunotherapy toxicity, host factors regulating efficacy and resistance, and neoadjuvant immunotherapy, all in the pursuit of creating better treatments. Please join in the conversation and network with investigators, from basic to translational scientists, from academia to industry.  

Lead Supporter

AbbVie
Bristol Myers Squibb

SUPPORTER

Janssen

PROFESSIONAL EDUCATIONAL GRANTS

Genentech
Merck
Pfizer

Continuing Medical Education Activity AMA PRA Category 1 Credits^TM available

#AACRtii22